|
|
Article: Spectrum Pharmaceuticals to Receive $5 Million Milestone Payment From PAR Pharmaceutical for Sumatriptan Injection.
- Article from:
- PR Newswire
- Article date:
- November 13, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
* Spectrum Received Tentative Approval for Sumatriptan Injection From the FDA in October 2006
IRVINE, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. today announced that it will receive a $5 million milestone payment under its agreement with Par Pharmaceutical Companies, Inc. for sumatriptan injection. Sumatriptan injection is a prescription medicine for the acute treatment of migraine attacks. The branded product, Imitrex(R), is marketed by GlaxoSmithKline.
"The tentative approval of sumatriptan injection and the subsequent payment we will receive from PAR Pharmaceutical is yet another milestone achieved by our team in the ...